U.S. Kidney Cyst Market Size, Share & Forecast 2026–2032

ID: MR-11678 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Kidney Cyst Market
  • ✓Market Size 2024: USD 2.4 billion
  • ✓Market Size 2032: USD 3.6 billion
  • ✓CAGR: 5.2%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Imaging Utilization Drives Volume: Incidental renal cyst detection rides on CT and ultrasound ordered for unrelated indications, so case volume tracks imaging utilization, not nephrology referrals. Bosniak IIF lesions require recurring surveillance scans, which favors GE HealthCare and Siemens Healthineers installed bases.
FINDING 02
Procedures Lag Drug Value: Procedural cyst treatment will not scale with prevalence because most simple cysts never need intervention. Future value sits in ADPKD drugs, where Otsuka's Jynarque is the only FDA-approved disease-modifying therapy today.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Radiology Network Contracts: Medical device and imaging suppliers should secure contracts with U.S. hospital outpatient radiology networks before Q4 2026, targeting Bosniak IIF follow-up protocols. Early contracts lock in recurring scanner utilization and reimbursed follow-up volume ahead of competitor consolidation.

Kidney Cyst Care in the United States: Market Overview

The U.S. kidney cyst market is distinctive because its value is generated mainly by detection rather than treatment. Simple renal cysts appear on a large share of adult abdominal scans, and the Bosniak classification system determines whether a lesion is dismissed, monitored, or referred for intervention. Consequently, imaging services and follow-up surveillance account for most spending, while drugs and procedures serve a smaller, specialized patient pool.

Relative to global norms, U.S. spending is more imaging-intensive and more reliant on outpatient radiology, reflecting high CT and ultrasound utilization and fee-for-service reimbursement. Analyst estimates place 2024 U.S. spending at roughly USD 2.4 billion, with about 60% tied to imaging and surveillance, 25% to autosomal dominant polycystic kidney disease (ADPKD) pharmaceuticals, and the balance to percutaneous and laparoscopic cyst-directed procedures. Europe's publicly funded systems, by contrast, concentrate follow-up in fewer, centralized centers.

Growth Drivers in U.S. Kidney Cyst Care

Three country-specific drivers sustain demand. First, Medicare fee-schedule coverage for CT abdomen and pelvis (CPT 74160 with contrast, 74150 without) and renal ultrasound (CPT 76770) keeps incidental detection reimbursed, anchoring scan volume. Second, the PKD Foundation estimates roughly 600,000 Americans live with ADPKD, a population that requires lifelong cyst surveillance and kidney function monitoring.

Third, the FDA approved tolvaptan (Jynarque) in 2018 for rapidly progressing ADPKD, and Medicare Part D coverage has converted that approval into recurring drug spend. The NIDDK-funded Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) validated total kidney volume imaging as a progression marker, which expands imaging use in specialist nephrology clinics.

Market Restraints and Entry Barriers in the U.S.

Entrants face several barriers. The Jynarque REMS program requires liver function monitoring and restricts dispensing to specialty pharmacies, adding distribution complexity. Imaging and ablation devices require FDA 510(k) clearance under 21 CFR Part 807, and hospital capital purchasing runs through group purchasing organizations such as Vizient and Premier, which favor incumbents with multi-year contracts.

Pricing pressure intensifies as Medicare negotiated prices under the Inflation Reduction Act begin applying to high-spend Part D products. Most simple cysts are asymptomatic and never reimbursed for treatment, so procedural volumes stay small and cannot scale, which limits returns for device entrants and keeps cyst-directed procedures a niche category.

Market Opportunities in U.S. Kidney Cyst Care

Near-term entry points include AI-assisted Bosniak classification software, which reduces radiologist reading time on indeterminate lesions. Analyst estimates place the addressable U.S. spend on AI-assisted characterization at roughly USD 180 million in 2025, based on surveillance reads across outpatient radiology networks and hospital imaging departments.

Ambulatory surgery centers offer a second opening for minimally invasive laparoscopic deroofing, which shifts cases from inpatient settings to lower-cost sites of care. Analyst estimates put this procedural niche near USD 95 million. A third opening lies in ADPKD monitoring platforms that track total kidney volume longitudinally, addressable at roughly USD 60 million in specialist nephrology practices.

Market at a Glance

MetricValue
Market Size 2024USD 2.4 billion
Market Size 2032USD 3.6 billion
Growth Rate (CAGR)5.2%
Most Critical Decision FactorReimbursement pathway for surveillance imaging and ADPKD drug coverage
Largest RegionSouth (Texas, Florida, and Georgia corridor)
Competitive StructureFragmented in imaging and procedures; concentrated in ADPKD pharmaceuticals

Leading Market Participants

  • Otsuka Pharmaceutical
  • Vertex Pharmaceuticals
  • Novartis
  • GE HealthCare
  • Siemens Healthineers
  • Philips
  • Canon Medical Systems USA
  • Medtronic
  • Boston Scientific
  • Cook Medical

Regulatory and Policy Environment

The FDA's Center for Drug Evaluation and Research administers the Jynarque REMS, while the Center for Devices and Radiological Health clears imaging and ablation hardware through 510(k) submissions, with a 90 FDA-day review goal. AI characterization software follows FDA's predetermined change control plan guidance, finalized in 2024. The CMS Physician Fee Schedule sets annual payment for CPT imaging codes, and ICD-10-CM codes N28.1 (acquired renal cyst) and Q61.2 (autosomal dominant polycystic kidney) drive claims classification.

The Inflation Reduction Act (Public Law 117-169) authorizes Medicare to negotiate prices for selected Part D drugs, with negotiated prices effective from 2026. The NIH's National Institute of Diabetes and Digestive and Kidney Diseases funds CRISP and related ADPKD research. State certificate-of-need programs in New York and North Carolina can require approval before imaging or ambulatory surgery capital expansions, so entrants must confirm state requirements before committing equipment budgets.

Long-Term Outlook for U.S. Kidney Cyst Care

By 2032, U.S. kidney cyst care will be defined by longer surveillance pathways rather than more procedures. Bosniak-guided follow-up imaging will expand as AI-assisted reads lower cost per study, shifting spend toward software-enabled outpatient radiology networks. Total kidney volume imaging will increasingly anchor ADPKD management in specialist nephrology clinics.

Drug economics will shape the largest revenue pool. Jynarque's current position and the Medicare negotiation cycle will compress pricing, while pipeline programs at Vertex and Novartis will expand ADPKD treatment options. Procedural cyst treatment will remain niche, with sclerotherapy and deroofing concentrated in ambulatory surgery centers.

Frequently Asked Questions

Entrants should target outpatient imaging networks, since surveillance scans generate recurring reimbursed volume under existing CPT codes. A device or software product needs FDA 510(k) clearance, which targets a 90 FDA-day review.
Medicare generally covers cyst-directed procedures only when cysts are symptomatic or complicated under medical necessity criteria. Coverage depends on documented Bosniak category and symptom records.
Jynarque requires a REMS program with liver function monitoring and specialty pharmacy dispensing. Pricing is also exposed to Medicare Part D negotiation under the Inflation Reduction Act.
Certificate-of-need laws in states such as New York and North Carolina can apply to imaging and ambulatory surgery capital expansions. Entrants should confirm state requirements before committing equipment budgets.
A licensing or distribution partnership with an established imaging OEM avoids the group purchasing organization contracting barrier. Partnerships also shorten the time to hospital purchasing committee approval.

Market Segmentation

By End User
  • Hospitals
  • Ambulatory Surgery Centers
  • Outpatient Imaging Centers
  • Nephrology Clinics
  • Urology Practices
By Diagnostic Modality
  • Computed Tomography
  • Ultrasound
  • Magnetic Resonance Imaging
  • Contrast-Enhanced Ultrasound
By Intervention Type
  • ADPKD Pharmaceuticals
  • Percutaneous Sclerotherapy
  • Laparoscopic Deroofing
  • Active Surveillance Only

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Kidney Cyst Care - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 End User Insights
4.1 Hospitals
4.2 Ambulatory Surgery Centers
4.3 Outpatient Imaging Centers
4.4 Nephrology Clinics
4.5 Others
Chapter 05 Diagnostic Modality Insights
5.1 Computed Tomography
5.2 Ultrasound
5.3 Magnetic Resonance Imaging
5.4 Contrast-Enhanced Ultrasound
5.5 Others
Chapter 06 Intervention Type Insights
6.1 ADPKD Pharmaceuticals
6.2 Percutaneous Sclerotherapy
6.3 Laparoscopic Deroofing
6.4 Active Surveillance Only
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Otsuka Pharmaceutical
7.2.2 Vertex Pharmaceuticals
7.2.3 Novartis
7.2.4 GE HealthCare
7.2.5 Siemens Healthineers
7.2.6 Philips
7.2.7 Canon Medical Systems USA
7.2.8 Medtronic
7.2.9 Boston Scientific
7.2.10 Cook Medical
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.